CJC-1295 with Dac

CJC-1295 (DAC) is a synthetic, long-acting growth hormone-releasing hormone (GHRH) analogue modified with a Drug Affinity Complex (DAC) that promotes reversible binding to albumin and substantially extends systemic exposure compared with shorter-acting GHRH analogues.

The extended pharmacokinetic profile makes CJC-1295 (DAC) particularly useful for research examining sustained GHRH-receptor signaling and downstream effects on the growth hormone (GH) / IGF-1 axis. Unlike CJC-1295 without DAC, which is designed for shorter exposure and more transient signaling, the DAC modification produces a considerably more prolonged pharmacological profile.
Research interest extends across endocrine physiology, body-composition biology, metabolic signaling, recovery, sleep-related pathways, and age-associated changes in the GH/IGF-1 axis.

Researchers have also investigated its effects on circulating GH and IGF-1 and the relationship between sustained GHRH signalling and downstream physiological responses.

Key Research Areas

- GH / IGF-1 axis and endocrine physiology

- GHRH-receptor signaling

- Pharmacokinetics and sustained peptide exposure

- Body-composition research

- Metabolic and energy-regulation pathways

- Recovery and exercise physiology

- Sleep-related endocrine research

- Cellular and age-associated GH-axis biology

At Kinetus Biolabs, CJC-1295 (DAC) is positioned as an investigational long-acting GHRH analogue for researchers studying sustained GH-axis signaling, endocrine physiology, pharmacokinetics, and related metabolic and body-composition pathways.

Kinetus Biolabs | Precision Science. Peak Potential.

Research Use Only — Not for Human Consumption.